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Systematic review
Statins are not associated with a decrease in all cause 
mortality in a high-risk primary prevention setting
Bernhard M Kaess,1 Ramachandran S Vasan2
Context
Low-density lipoprotein (LDL) cholesterol (LDL-C) is 
a risk factor for cardiovascular disease (CVD). Statins 
(3-hydroxy-3-methylglutaryl-coenzyme A reductase 
inhibitors) lower LDL-C concentrations by about 30–50% 
and have been shown to reduce mortality in patients with 
prevalent CVD. However, it is not clear whether statin 
treatment is benefi cial in a primary prevention setting, 
that is in people without prevalent CVD who are at rela-
tively lower risk. The recent results of the JUPITER trial1 
have fuelled an intense debate whether statins should be 
given for primary prevention of CVD.
Methods
The authors performed a literature search in MEDLINE and 
Cochrane Collaboration databases to identify randomised 
controlled trials of statin use comprising patients without 
prevalent CVD at baseline. For trials partly containing 
CVD patients, the authors obtained tabular data for the 
individuals without a history of CVD. A meta-analysis 
was performed using both random effects and fi xed 
effects models. The primary outcome of interest was all-
cause mortality. Potential publication bias was assessed 
by the funnel plot and Egger’s test.
Findings
The authors indentifi ed 11 studies that met their inclusion 
criteria and that provided the required data, two of them 
containing only patients with diabetes. In total, 65 229 
patients with an average follow-up of 3.7 years were anal-
ysed, resulting in approximately 244 000 person-years of 
observation. Mean age at recruitment varied from 51 to 
75 years. The age at time of recruitment was the only 
baseline correlate of mortality, while LDL-C concentra-
tion was not predictive of mortality. Statin therapy was 
not associated with a signifi cant survival benefi t (RR for 
statin users compared to non-users of: 0.91, 95% CI 0.83 
to 1.01; and 0.93, 95% CI 0.86 to 1.00, in random effects 
and fi xed effects models, respectively). The exclusion 
of the two trials comprising only patients with diabetes 
did not substantively change these results. Furthermore, 
the authors did not fi nd a correlation between mortal-
ity reduction and baseline LDL-C concentration or with 
relative LDL-C reduction in the treatment arm. A relevant 
publication bias could not be detected.
Commentary
The authors present a meta-analysis of the effects of statin 
treatment on all-cause mortality in intermediate to high-
risk patients without prevalent CVD. This investigation is 
by far the largest analysis of statin therapy in a purely pri-
mary prevention setting. Although the cohorts varied con-
siderably with respect to the recruitment strategy, mean 
age and cardiovascular risk profi le, the authors observed 
a consistent null result (for statin benefi t) independent of 
mean baseline LDL concentration and mean LDL-C reduc-
tion in the treatment arm and without evidence of relevant 
heterogeneity across cohorts. A non-signifi cant ~8% risk 
reduction in a study of this size excludes a clinically rel-
evant survival benefi t for statin therapy in the assessed 
population over the limited observation time.
This study therefore questions the widespread prac-
tice of prescribing statins to middle-aged patients with 
an average cardiovascular risk profi le who do not have 
overt CVD. The cohorts included in the meta-analysis 
had a mean mortality of 11.4/1000 person-years (in the 
placebo-arms), and therefore represent an intermediate 
to high-risk population. The inference can be made that 
individuals with lower cardiovascular risk are likely to 
benefi t even less from statin therapy.
Nevertheless, there are some questions that this study 
cannot answer. First, the mean follow-up is only 3.7 years, 
hence conclusions on potential long-term benefi ts of sta-
tin intake cannot be drawn. Some investigators argue that 
long-term exposure to higher LDL cholesterol is likely to 
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Taken together, the study is the fi rst to meta-analyse 
statin therapy in a purely primary prevention setting. Its 
conclusive null result (for statin benefi t on all-cause mor-
tality) raises important questions about the current prac-
tice of widespread use of statins for primary prevention of 
CVD in individuals with average cardiovascular risk.
Competing interests None.
References
 1. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to 
prevent vascular events in men and women with elevated 
C-reactive protein. N Engl J Med 2008;359:2195–207.
 2. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident 
diabetes: a collaborative meta-analysis of randomised statin 
trials. Lancet 2010;375:735–42.
increase lifetime cardiovascular burden and therefore ben-
efi ts from lowering of LDL cholesterol could be expected on 
long-term follow-up. Other experts have noted the potential 
for drug toxicity that may be accumulating over years of 
statin intake, including risk of developing diabetes.2 Long-
term studies are warranted to address this issue. Second, all-
cause mortality is an end point that has a low frequency in 
a primary prevention setting. Major cardiovascular events 
and cardiovascular morbidity (and associated impairment in 
quality of life) may be important outcomes that more closely 
refl ect treatment benefi ts in a primary prevention popula-
tion seen in general practice. Third, since the meta-analysis 
did not have access to individual-level data, subgroup anal-
yses (such as stratifi ed by gender, age, risk profi le) could not 
be performed. This study cannot answer the crucial question 
if there are select subgroups that may actually benefi t from 
statin therapy in a primary prevention setting.
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